Summary
- •Scale: ₹1,757 Cr. Mainboard issue.
- •Timeline: Bidding from 24 August 2026 to 27 August 2026.
- •Pricing: ₹938 to ₹988 per share.
Symbiotec Pharmalab officially launches its Initial Public Offering (IPO) to raise capital from the primary markets. As institutional and retail demand remains robust across the broader equity spectrum, this issue presents a highly anticipated opportunity for portfolio allocation.
Financial Trajectory
Evaluating the statutory financial disclosures, Symbiotec Pharmalab has demonstrated consistent revenue acceleration, posting a 20.59% shift in recent periods. Bottom-line profitability metrics reveal a 9.83% adjustment in Profit After Tax (PAT), indicating strong operational leverage and margin expansion. Investors must strictly compare these metrics against listed peers before allocating capital.
The definitive basis of allotment is projected for 28 August 2026, paving the way for secondary market listing on 01 September 2026.
Sources & Verification
- Financial Data:Extracted directly from the company's Draft Red Herring Prospectus (DRHP) and official exchange filings (BSE/NSE).
- Market Premium:Aggregated from unregulated grey market dealers. GMP is unofficial, indicative only, and does not guarantee listing performance.
- Review Process:Data and textual analysis independently verified by the IPO Chowk Research Desk.